Dissemination and Implementation Research in Health (PAR-25-144)

Applications are due by 5:00 PM local time of the applicant organization on the applicable listed application due date.

The earliest submission date is January 05, 2025.

The funding opportunity expires January 08, 2028.

Any errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.

All applications must be within the scope of the mission of one of the listed Institutes/Centers.

All applications must be within the scope of the mission of at least one participating Institute or Center.

Applications proposing to test therapies, imaging, diagnostics, biologics, or devices, including first-in-human studies or drug/device safety trials, are non-responsive.

Applications proposing to test an intervention in an efficacy trial are non-responsive.

For applications seeking NEI support under this funding opportunity, clinical trials must not be greater than minimal risk.

For clinical trial proposals to NIA, D&I strategies studied should be limited to strategies to disseminate and/or implement interventions that have evidence of efficacy/potency and evidence that the intervention can be delivered in the community with fidelity.

Applicants applying to NIAID should identify partnerships with relevant policy and/or program leaders who have stated a commitment to evaluate and incorporate changes proven successful, cost-effective, and relevant to NIAID's mission.

NIAID will not accept clinical trials using new drugs or diagnostic tools, or existing drugs or diagnostics for new purposes, in response to this NOFO.

Adaptations or augmentations of existing implementation strategies should only be undertaken when there is an empirical rationale, a clear hypothesis for how and why the adaptation or augmentation will enhance outcomes, and evidence suggesting substantial improvement in implementation, clinical, or functional outcomes.

Applications considered by NCCIH must not propose trials of regulated products for indications that have not been approved or cleared by the U.S. Food and Drug Administration.

NCCIH will only support applications that include complementary and integrative health approaches.

Applications assigned to NICHD must address one or more NICHD priority populations: infants, children and adolescents including those transitioning to adult health care; pregnant, peripartum, postpartum, or lactating individuals; individuals of reproductive age regarding gynecologic and reproductive health care; individuals of any age with intellectual and developmental disabilities; or individuals of any age with physical disabilities.

NIDCD will only accept low-risk clinical trials under this funding opportunity.

For this funding announcement, NINDS will support only mechanistic clinical trials, defined as studies designed to understand a behavioral process or the mechanism of action of an intervention, rather than whether it works or is safe.

Only New, Renewal, Resubmission, and Revision application types are allowed for this NOFO.

Applications may either propose or not propose clinical trial(s).

Foreign organizations, non-domestic components of U.S. organizations, and foreign components are eligible or allowed to apply under the stated conditions.

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

Foreign (non-U.S.) organizations must follow the policies and procedures for foreign organizations described in the NIH Grants Policy Statement and the How to Apply- Application Guide.